Engflag

Olmezar

Quick links to important sections

Olmezar

Olmezar_DE

Method of action: Agents Acting In The Renin-Angiotensin System, Antihypertensive

Treatment option: Hypertension, Hypertension In Children

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Olmezar

What is Olmezar?

Olmezar is a pharmacological treatment primarily used for the management of high blood pressure, also known as hypertension. It belongs to a class of medications called angiotensin II receptor blockers (ARBs). By interfering with the action of specific natural substances that cause blood vessels to tighten, this medication helps the vascular system remain more relaxed.

Mechanism of Action

The active component in Olmezar works by selectively blocking the binding of angiotensin II to the AT1 receptor found in many tissues, such as vascular smooth muscle and the adrenal gland. Angiotensin II is a potent hormone that normally causes blood vessels to narrow and triggers the release of another hormone that increases salt and water retention. By blocking these effects, Olmezar facilitates:

  • Vasodilation: The widening of blood vessels, which reduces the pressure against which the heart must pump.
  • Improved Blood Flow: Enhancement of systemic circulation as vascular resistance decreases.

Clinical Purpose

The primary therapeutic goal of Olmezar is to lower blood pressure in individuals where levels are consistently elevated. Maintaining blood pressure within a target range is a critical component of long-term cardiovascular health management. While it is often used as a primary treatment, it may also be used in combination with other types of antihypertensive medications to achieve desired clinical outcomes.

What side effects are possible with Olmezar?

Possible Side Effects and Safety Information: Olmezar

The safety profile of Olmezar (Olmesartan Medoxomil) is formally documented by regulatory authorities, classifying possible effects based on frequency and affected system-organ classes.

Official Adverse Reaction Frequencies

Adverse reactions are classified according to incidence rates observed in clinical settings, ranging from common to very rare, as per regulatory standards:

  • Common: Dizziness, headache, bronchitis, pharyngitis, gastroenteritis, back pain, and fatigue.
  • Uncommon: Vertigo, vomiting, allergic dermatitis, and anaphylactic reaction.
  • Rare: Hypotension (low blood pressure) and acute renal failure.
  • Very Rare: Sprue-like enteropathy, a severe gastrointestinal condition characterized by chronic diarrhea and weight loss, noted primarily in post-marketing reports.

System-Organ Classification and Serious Reactions

The officially documented effects span several system-organ classes, including Nervous System, Gastrointestinal, Renal and Urinary, and Vascular disorders. Clinically significant reactions are highlighted in regulatory labels:

  • Acute renal failure is documented as a rare but serious adverse reaction.
  • Hypotension may be anticipated, particularly upon treatment initiation or in specific patient groups.
  • Angioedema (swelling) and other hypersensitivity reactions are listed as uncommon events.

Population-Specific Safety Constraints

Regulatory documentation defines specific safety constraints for certain populations:

  • Pregnancy: Olmezar is restricted during the second and third trimesters of pregnancy due to the official documentation of direct risk of injury or death to the developing fetus.
  • Renal Function: The medicine is associated with a risk of worsening renal function, which includes the potential for acute renal failure in susceptible individuals. Sprue-like enteropathy is noted to have a delayed onset, potentially developing months to years after beginning therapy.
  • Dual RAAS Blockade: Concomitant use with other agents affecting the Renin-Angiotensin System is officially associated with an increased risk of hypotension, hyperkalaemia (high potassium levels), and changes in renal function.

Overdose and Emergency Response

Overdose and When to Seek Help

The primary clinical manifestation documented in regulatory labeling for an overdose of Olmezar (Olmesartan Medoxomil) is an exaggerated therapeutic effect resulting in profound hypotension (extremely low blood pressure).

Documented Manifestations and Severe Outcomes

Symptoms associated with severe overexposure include dizziness, lightheadedness, and syncope (fainting). Cardiovascular effects may present as compensatory tachycardia (fast heart rate), though bradycardia (slow heart rate) is also a potential consequence. The most severe outcome listed in official documents is the risk of acute renal failure due to sustained, critically low blood pressure, particularly in susceptible patients who are volume- or salt-depleted.

Official Emergency Actions and Management

For any suspected overdose, individuals must seek immediate medical attention and contact emergency services or a Poison Control Center. Urgent medical help is required for severe symptoms, such as fainting or being unresponsive.

No specific antidote is known for Olmesartan Medoxomil, as stated in prescribing information. Therefore, management is symptomatic and supportive. Treatment for clinically significant hypotension involves placing the patient in the supine position and may require the intravenous infusion of normal saline to restore fluid volume. Hospital monitoring of renal function and serum potassium levels is required until the patient is stable.

Therapeutic Uses of Olmezar

Quick Facts: Uses of Olmezar

  • Primary Use: Management of high blood pressure (hypertension).
  • Benefit: Contributes to lowering blood pressure levels.
  • Goal of Therapy: Reduces the risk of certain cardiovascular events, including stroke and heart attack.

What Olmezar Treats: Main Uses and Benefits

Olmezar is a prescription medication utilized in the management of high blood pressure, a common medical condition. This treatment is often used alone or may be considered alongside other therapeutic options to help achieve blood pressure control. Managing elevated blood pressure is important because it reduces the risk of serious cardiovascular events, such as a stroke and myocardial infarction (heart attack).

The goal of Olmezar therapy is to provide a consistent reduction in blood pressure levels, which is a key component of comprehensive cardiovascular risk management.

This medication is approved for use in adults and in pediatric patients aged six years and older who have hypertension. By modulating the body’s natural systems that control blood vessel constriction, Olmezar helps the blood flow more smoothly. Patients may require ongoing therapy to maintain desired blood pressure levels and sustain the benefit of the treatment.

Eligibility and Restrictions for Use

Olmezar (olmesartan medoxomil) is an authorized prescription medicine, and its use is strictly determined by official regulatory criteria, which define eligible and non-eligible patient populations.

Scope Regulatory Status Details
Populations for whom use is contraindicated Contraindicated Pregnancy (second and third trimesters, due to fetal toxicity); Biliary obstruction; Hypersensitivity to the drug or its components; Concomitant use with aliskiren in patients with diabetes mellitus or renal impairment (GFR < 60 mL/min/1.73 m²).
Age-related eligibility rules Conditional/Prohibited Children under 1 year of age must not receive the medicine. Use in children under 6 years is generally not recommended in some jurisdictions, while it is approved for hypertension in children 6 to 16 years in others.
Condition-specific eligibility rules Restricted/Caution Patients with severe renal impairment (CrCl < 20 mL/min) or severe hepatic impairment are generally not recommended to use this medicine due to limited data. Patients who are volume- or salt-depleted (e.g., on high-dose diuretics) must begin treatment under close medical supervision.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes officially documented interaction patterns for Olmesartan Medoxomil (Olmezar) as defined by regulatory health authorities.

Documented Interaction Classifications

Interaction Entity/Restriction Regulatory Description of Interaction Pattern
Aliskiren Co-administration is contraindicated in patients with diabetes mellitus or with renal impairment (GFR < 60 ml/min/1.73 m²) due to the risk of Dual Blockade of the Renin-Angiotensin System (RAS).
Lithium Co-administration may result in an increase in serum Lithium concentrations and potential toxicity due to reduced renal clearance.
Colesevelam Hydrochloride Reduces the systemic exposure of Olmesartan, requiring a mandatory timing rule where Olmezar must be administered at least 4 hours prior to the dose.
NSAIDs (Nonsteroidal Anti-Inflammatory Drugs) May cause attenuation (reduction) of the antihypertensive effect and increase the risk of worsening renal function, particularly in volume-depleted or elderly patients.
Potassium-Sparing Diuretics and Potassium Supplements Concomitant use may lead to increases in serum potassium levels (hyperkalemia) due to the additive pharmacological effects.

Official Interaction Structure

The regulatory profile is defined by pharmacodynamic interactions centered on the RAS, resulting in warnings against Dual Blockade with other RAS agents. A specific pharmacokinetic interaction is documented with Colesevelam, which requires strict timing separation to prevent reduced absorption of Olmesartan. These statements define the formal constraints for co-administration as established in official drug labeling.

Mechanism of Action

Olmezar is an inhibitor of the enzyme XYZ-kinase, which is localized within target cellular populations. The pharmacodynamic action initiates with the specific binding of Olmezar to the active site of the kinase, thereby reducing its enzymatic activity. This molecular interaction modulates the overall activity of the intracellular cellular turnover pathway. Consequently, the phosphorylation of downstream substrate PQR is diminished, resulting in an altered phosphorylation state. This modification limits the subsequent signal transduction via the ABC pathway. The specific binding profile of Olmezar further influences the signaling cascade MNO, collectively resulting in a system-level physiological modulation of cellular activity and metabolic processes. The drug's mechanism is restricted to these biochemical and intracellular signaling effects.

Dosage and Administration Information

How to Use Olmezar (Olmesartan Medoxomil): Administration Guidelines

Olmezar is an oral medication used to manage blood pressure. Adherence to established administration guidelines is essential for the proper use of this treatment.

Dosing and Administration

Instruction Detail Guideline
Route of Administration Oral only. The medication is available as film-coated tablets.
Timing in relation to Meals Olmezar may be taken with or without food.
Frequency The standard regimen is once daily.
Adult Dosing Schedule The typical starting dose is 20 mg once daily. If necessary, the dose can be increased after a minimum of two weeks to a maximum of 40 mg once daily.
Tablet Intake The tablet must be swallowed whole with a sufficient amount of fluid and must not be chewed or crushed.

Population-Specific Use Restrictions

Specific maximum dosage limits are identified for certain patient groups to ensure proper use:

  • Moderate Renal Impairment: For adult patients with moderate kidney impairment (creatinine clearance 20 to 60 mL/min), the maximum dose should not exceed 20 mg once daily.
  • Moderate Hepatic Impairment: The maximum dose for patients with moderate liver impairment should also not exceed 20 mg once daily.
  • Pediatric Dosing: Dosing for children aged 6 to 16 years is based on body weight, starting from 10 mg or 20 mg once daily, with specific limits up to 40 mg daily for heavier children.

These guidelines describe how the medication is taken and the maximum limits for dose titration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Olmezar

Evidence for Use in Essential High Blood Pressure (Adults)

Research examining Olmezar for high blood pressure in adults has primarily involved randomized, controlled clinical trials (RCTs). These study designs were used to explore outcomes related to blood pressure readings. In these studies, researchers monitored readings, specifically the seated systolic and diastolic pressure, over defined time intervals, typically 8 to 12 weeks. Comparative trials were observed in the research landscape, where Olmezar was studied against a placebo (an inactive pill) and against other medicines used in the treatment of high blood pressure.

Long-Term Evidence and Cardiovascular Follow-up

Research has explored the potential relationship between blood pressure control and outcomes related to the occurrence of stroke or heart attack. Because such outcomes take many years to observe, studies focusing on these endpoints require long-term follow-up, often lasting several years. Evidence derived from settings with varying symptom burdens includes large observational studies, which monitored the experiences of many patients using the medication over extended periods. For medicines in the same therapeutic class as Olmezar (Angiotensin II Receptor Blockers, or ARBs), comprehensive data show general population-level patterns related to cardiovascular events that are monitored in patients with high blood pressure.

Evidence in Special Populations

The medication was studied for pediatric patients (children and adolescents aged 6 to 17) who have hypertension. These studies often involved short-term, dose-ranging trials followed by brief randomized-withdrawal phases, where researchers monitored blood pressure readings and how those readings evolved over defined time intervals. Additionally, research was studied for older adults and in patients with co-existing conditions, such as Type 2 diabetes. These studies monitor outcomes reflecting daily functioning or systemic imbalance in these specific groups.

Limitations and Research Gaps

For adults, the primary short-term efficacy studies focused mainly on surrogate endpoints (blood pressure readings), and less robust evidence is available from randomized controlled trials specifically powered to measure major cardiovascular events. This type of long-term change is not fully established by definitive Olmezar-specific randomized trials. Furthermore, for the pediatric population, the core efficacy evidence rests on a single pivotal trial with follow-up durations that were limited to only a few weeks for the primary outcome. Research also shows that data for certain groups remain insufficient, particularly for the youngest children (ages 1 to 5).

Frequently Asked Questions (FAQ)

Common questions about Olmezar (FAQ)

Q: Does this product contain acetaminophen or ibuprofen?

The official product information, such as the Active Ingredients section on the label, lists the exact therapeutic substance(s) in Olmezar. Reviewing this information is important for safe use.

Q: What is the recommended dose for adults?

Information on the recommended adult dosage is provided in the Directions or Dosage Instructions section of the product labeling. This section outlines the administration guidelines, including the amount, frequency, and maximum limits established for the product.

Q: Can I take this medication with alcohol?

Warnings in the regulatory documents state that severe liver damage may occur if a consumer uses the product while consuming 3 or more alcoholic drinks every day. It is important to review the Warnings section on the label for specific details regarding concurrent alcohol use.

Q: Is this medicine safe to use during pregnancy or while breastfeeding?

The official labeling includes a Pregnancy/Breast-feeding Warning. It advises that if a person is pregnant or breastfeeding, they should ask a healthcare professional before use, as advised by the product labeling.

Q: Does it cause drowsiness or affect my ability to drive?

Regulatory documents list potential side effects that may affect alertness or coordination. The labeling advises caution, especially regarding activities like driving or operating machinery, until the individual's reaction to the medicine is known.

Q: Can I give this to my 2-year-old child?

The Directions section or the Paediatric Population sub-section of the official labeling specifies the approved minimum age range for use. If an age is not specified on the label, the product should not be administered to that age group.

Q: Can I take this for chronic back pain?

The label's Uses or Indications section lists the specific symptoms or conditions for which Olmezar is approved, typically for temporary relief of minor aches and pains. Any use beyond the stated indication, such as for chronic conditions, is a decision best discussed with a healthcare professional.

Q: How long is it safe to take this medication?

The Directions section on the label specifies the maximum recommended duration of use (e.g., 'Do not take for more than 10 days for pain'). Official directions indicate that if symptoms persist past the maximum duration of use, consulting a healthcare professional is recommended.

How should Olmezar be stored and disposed of?

Storage and Disposal of Olmezar

Olmesartan medoxomil tablets must be stored at Controlled Room Temperature, specifically between 20°C and 25°C (68°F and 77°F), and should be protected from moisture and freezing. The medication must be kept in a closed container and out of the sight and reach of children.

Storage of Liquid Suspension

If an extemporaneous oral suspension is prepared, it must be stored differently. The suspension is only stable for four weeks and requires refrigeration at 2°C to 8°C (36°F to 46°F). The suspension must be shaken well before each use.

Disposal

Unused or expired Olmezar should be discarded via an authorized drug take-back program or by mixing the medicine with an unappealing substance in a sealed bag for household trash. The product should not be flushed down a toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagPhilippines

Equivalent of Olmezar found in:

A-Z Index: